Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016; New Report Launched

Matrix Protein 1 (M1 or M) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by Companies and remaining by the Universities/Institutes. Matrix Protein 1 (M1 or M) – Pipeline Review, H2 2016, outlays comprehensive information on the Matrix Protein 1 (M1 or M) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Matrix Protein 1 (M1 or M) M1 protein is a matrix protein of the influenza virus. It forms a coat inside the viral envelope. It plays critical roles in virus replication, entry and uncoating to assembly and budding of the virus particle. M1 binding to ribonucleocapsids (RNPs) in nucleus seems to inhibit viral transcription. The molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

For more information Visit at: http://mrr.cm/3Sz

Related Reports;

Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Review, H2 2016 - Visit at - http://mrr.cm/3SK

Saniona AB - Product Pipeline Review - 2016 - Visit at - http://mrr.cm/3Sr

Meniere Disease - Pipeline Review, H2 2016 - Visit at - http://mrr.cm/3SH

Osteosarcoma - Pipeline Review, H2 2016 - Visit at - http://mrr.cm/3SV